14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DSGN vs IMCR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Design Therapeutics, Inc. (DSGN) captures the overall head-to-head institutional edge over Immunocore Holdings plc (IMCR) on higher Unified Composite conviction (49.9/100 HOLD vs. 46.5/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality), while IMCR wins 5–1 across the 6-pillar growth and valuation breakdown. DSGN trades at $9.94 (N/M Forward P/E, 0.0% operating margin) versus IMCR at $29.10 (23.8x Forward P/E, -2.2% operating margin).
Growth vs. Quality Trade-Off: DSGN earns the overall head-to-head edge with a stronger Unified Composite Score (49.9/100 HOLD vs. IMCR 46.5/100 HOLD) and 1.32β · 61% Vol risk profile, whereas IMCR leads top-line expansion (-1.4% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile IMCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DSGN vs IMCR. Trailing 12-month operating profitability (DSGN 0.0% vs IMCR -2.2%) and valuation multiples (DSGN N/M vs IMCR 23.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.6B market capitalization and -2.2% operating margin.
OpEx & R&D Reinvestment36.7% of Rev ($158M)
90D Engineering Disclosures0 Published
Investor FAQ DSGN vs IMCR Key Questions & Quantitative Answers
As of Nov 16, 2026, Design Therapeutics, Inc. (DSGN) captures the overall head-to-head institutional edge over Immunocore Holdings plc (IMCR) on higher Unified Composite conviction (49.9/100 HOLD vs. 46.5/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality), while IMCR wins 5–1 across the 6-pillar growth and valuation breakdown. DSGN trades at $9.94 (N/M Forward P/E, 0.0% operating margin) versus IMCR at $29.10 (23.8x Forward P/E, -2.2% operating margin). Growth vs. Quality Trade-Off: DSGN earns the overall head-to-head edge with a stronger Unified Composite Score (49.9/100 HOLD vs. IMCR 46.5/100 HOLD) and 1.32β · 61% Vol risk profile, whereas IMCR leads top-line expansion (-1.4% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile IMCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IMCR leads the Growth & Scale pillar: DSGN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with IMCR at -1.4% YoY revenue growth and +150.0% YoY earnings growth on $429M TTM revenue (34.5% gross margin, -2.2% operating margin). On trailing 12-month operating scale, DSGN generates $33,000 in USD-normalized revenue versus $429M for IMCR. In operating R&D and SG&A reinvestment, DSGN deploys N/A (0 90-day corporate R&D disclosures) versus 36.7% of Rev ($158M) (0 disclosures) for IMCR.
IMCR screens cheaper on headline valuation multiples. DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas IMCR trades at 23.8x Forward P/E, 23.8x Trailing P/E, N/M PEG, and 3.7x EV/Revenue (-1.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DSGN (-36.9% ROE) versus IMCR (-7.9% ROE) capital efficiency.
In options market volatility and institutional positioning, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk). By comparison, IMCR carries 56.7% implied volatility (10th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.63β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.